Posted by Michael Wonder on 23 Apr 2021
Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
23 April 2021 - VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy Jemperli (dostarlimab-gxly).
Roche today announced U.S. FDA approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients.
MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication.
